Barinthus Biotherapeutics (STU:2AB) 3-Month Share Buyback Ratio: 0.00% (As of Mar. 2026 )


STU:2AB Barinthus Biotherapeutics PLC STU:2AB
14 GF Score
Price €0.53
GF Value €0.97
! 1 Warning Sign
View Full Analysis

What is Barinthus Biotherapeutics 3-Month Share Buyback Ratio?

Barinthus Biotherapeutics STU:2AB +1.92% 14 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus rates STU:2AB with a GF Score™ of 14/100 and a GF Value™ of €0.97. The stock has 1 warning sign investors should review.

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Barinthus Biotherapeutics's current 3-Month Share Buyback Ratio was 0.00%.

Barinthus Biotherapeutics  (STU:2AB) 3-Month Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Barinthus Biotherapeutics 3-Month Share Buyback Ratio Related Terms

STU:2AB vs VTGN, PSTV, PVCT: 3-Month Share Buyback Ratio Comparison

For the Biotechnology subindustry, Barinthus Biotherapeutics's 3-Month Share Buyback Ratio, along with its competitors' market caps and 3-Month Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Barinthus Biotherapeutics 3-Month Share Buyback Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Barinthus Biotherapeutics's 3-Month Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Barinthus Biotherapeutics's 3-Month Share Buyback Ratio falls into.


STU:2AB
14GF Score
Barinthus Biotherapeutics PLC STU:2AB
3-Month Share Buyback Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Barinthus Biotherapeutics 3-Month Share Buyback Ratio Calculation

Barinthus Biotherapeutics's 3-Month Share Buyback Ratio for the quarter that ended in Mar. 2026 is calculated as

3-Month Share Buyback Ratio=(Shares Outstanding (EOP) (Dec. 2025 ) - Shares Outstanding (EOP) (Mar. 2026 )) / Shares Outstanding (EOP) (Dec. 2025 )
=(40.849 - 40.849) / 40.849
=0.00%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a 3-Month Share Buyback Ratio of 0.00 mean?
Barinthus Biotherapeutics (STU:2AB) has a 3-Month Share Buyback Ratio of 0.00 as of Mar. 2026. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Barinthus Biotherapeutics and its competitors.
Is Barinthus Biotherapeutics' 3-Month Share Buyback Ratio too high?
Barinthus Biotherapeutics' current 3-Month Share Buyback Ratio is 0.00. Overall, Barinthus Biotherapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Barinthus Biotherapeutics' 3-Month Share Buyback Ratio compare to VTGN and PSTV?
Barinthus Biotherapeutics' 3-Month Share Buyback Ratio of 0.00 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Month Share Buyback Ratio for a Biotechnology company?
A good 3-Month Share Buyback Ratio depends on the Biotechnology industry context. However, 3-Month Share Buyback Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Month Share Buyback Ratio mean?
A high 3-Month Share Buyback Ratio can signal that a stock is expensive relative to its fundamentals. The 3-Month Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past three months, calculated as the percentage change in shares outstanding from the previous quarter to the current quarter. View historical data for Barinthus Biotherapeutics and its competitors. Barinthus Biotherapeutics's current 3-Month Share Buyback Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Barinthus Biotherapeutics stock overvalued right now?
Barinthus Biotherapeutics (STU:2AB) has a current 3-Month Share Buyback Ratio of 0.00. The stock's GF Value™ is €0.97, compared to a current price of €0.53 — trading 45.4% below its estimated fair value. The current 3-Month Share Buyback Ratio is 0.00. Barinthus Biotherapeutics' overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Month Share Buyback Ratio calculated?
3-Month Share Buyback Ratio is calculated from a company's financial statements. For Barinthus Biotherapeutics (STU:2AB), the current 3-Month Share Buyback Ratio is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Barinthus Biotherapeutics (STU:2AB) Overvalued in 2026?

Based on GuruFocus' analysis, Barinthus Biotherapeutics stock appears to be undervalued. The current stock price of €0.53 is trading 45.4% below its estimated GF Value™ of €0.97.

Key valuation signals for STU:2AB:

  • 3-Month Share Buyback Ratio: 0.00
  • GF Value™: €0.97 vs. price of €0.53 (45.4% below fair value)
  • GF Score™: 14/100 with 1 warning sign

No single metric tells the full story. See the STU:2AB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Barinthus Biotherapeutics Business Description

Other Exchanges BRNS:USA
Address 20400 Century Boulevard, Suite 210, Germantown, MD, USA, 20874
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company focused on developing novel immunotherapeutic drug candidates for treating autoimmune and inflammatory diseases. The company is prioritizing the development of its proprietary SNAP-TI platform, designed to promote immune tolerance, with its lead candidate VTP-1000 targeting celiac disease. It is also developing VTP-300 for chronic hepatitis B using viral vector platform technologies, aimed at inducing disease-specific immune responses.
14GF Score

Get the complete analysis for STU:2AB

3-Month Share Buyback Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.53
Price
€0.97
GF Value